Motor neurone drug now being set for clinical tests

LONDON: A superdrug that could convert motor neurone disease from a cruel killer into a manageable chronic condition is on track for testing within five years.

The extraordinary breakthrough has received essential funding from FightMND, the charity founded by late AFL great Neale Daniher.

The organisation, which runs The Big Freeze, the country’s premier fundraising and awareness campaign for MND, has been pumping money into research since 2014.

University of Queensland scientists collaborated with overseas experts to develop the drug R8Y, which activates a hard-to-target immune receptor.

The Indian Institute of Technology, the University of Tokyo and Sungkyunkwan University, South Korea worked with the Queenslanders to uncover the molecular make-up of the receptor found on the surface of many immune cells called C5aR2.

Professor Trent Woodruff, of UQ’s School of Biomedical Sciences, said the drug provided a unique tool to study C5aR2 in detail, opening up new possibilities for anti-inflammatory therapies.

“With this knowledge, it’s possible we could have an anti-inflammatory drug treatment for testing in MND patients within five years, possibly turning the disease into a long-term chronic condition rather than an acute terminal illness,’’ Professor Woodruff said.

He said that funding from FightMND had been essential to progress the treatment.

“The drug we developed as part of this study, called R8Y, is a molecule that specifically binds to C5aR2,” Professor Woodruff said.

“This allowed us to see the structure and function of the receptor, which led to the discovery that C5aR2 does not behave like most other receptors.

“It is unable to couple to G proteins – a rare and important distinction which explains why it’s been so difficult to target and why its role in inflammation has been so elusive.”

International partners used the UQ-developed drug to create a model of the drug bound to the receptor, in turn giving information on how the drug binds to the receptor and how the receptor signals.

Using this knowledge, the UQ team is now working to develop better anti-inflammatory drugs for hard-to-treat neurodegenerative conditions such as MND, Parkinson’s and Alzheimer’s disease.

Associate Professor Richard Clark said the achievement was possible only through the expertise at UQ and its international partners.

“This global effort demonstrates the power of cross-disciplinary and cross-border collaboration in tackling complex biomedical challenges,” he said.

FightMND’s cure research manager Michelle Kouspou said the charity was proud to fund the research. It was also funded by a National Health and Medical Research Council grant and is published today in Molecular Cell.